Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US 3 min read Business Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US News Streamline 2 years ago OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals...Read More
